Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127018) titled 'Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis' on June 23.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
Refractory Autoimmune Encephalitis, Refractory Autoimmune Cerebellitis
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-06-24
Target Sample Size: Experimental group:12;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=329300
Published by HT Digital Co...